特發性血小板減少性紫癜治療全球市場研究報告——2023-2030 年行業分析、規模、份額、增長、趨勢和預測

2023-2030 年研究期間，全球對特發性血小板減少性紫癜治療市場的需求將以 8.52% 的複合年增長率增長，從 2022 年的 7.0059 億美元增長到 2030 年的近 13.4754 億美元 預計將達到美元市場規模.

特發性血小板減少性紫癜 (ITP) 是一種自身免疫性疾病，會導致血液中血小板數量減少。 血小板是血液正常凝結所必需的，血小板數量少會導致出血過多和瘀傷。 ITP 療法是指用於管理和治療特發性血小板減少性紫癜的藥物、療法和醫療器械。

市場動態：

由於人口老齡化和自身免疫性疾病增加等因素，ITP 在世界範圍內的患病率正在上升。 這推動了 ITP 治療市場的需求。 ITP 療法的技術進步，例如生物製劑的開發，正在改善治療效果並推動市場增長。 世界各國政府正在提供財政支持和激勵措施，以加速 ITP 療法的開發和採用，從而推動市場增長。 隨著越來越多的人尋求有效治療，對 ITP 及其治療的認識不斷提高，推動了對 ITP 治療的需求。 儘管有一些治療方法可用，但對更有效和負擔得起的 ITP 療法的未滿足需求仍然很高，這推動了對新療法和改進療法的需求。 單克隆抗體等生物製劑市場的擴大以及這些藥物作為 IT□□P 治療藥物的日益普及有望推動 ITP 治療藥物市場的增長。 保險公司對 ITP 藥物的承保使 ITP 患者更容易獲得和負擔得起這些藥物，從而推動了對這些藥物的需求。

這份研究報告解釋了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還可以全面評估全球特發性血小板減少性紫癜市場的每個部分。 特發性血小板減少性紫癜藥物行業的發展和趨勢為這項研究提供了一個整體方法。

市場細分：

特發性血小板減少性紫癜治療市場報告的這一部分提供了國家/地區級別的細分市場的詳細數據，從而幫助戰略家針對人口統計數據和他們各自產品或服務的即將到來的機會。幫助確定

按產品

• 腎上腺皮質類固醇
• 用於靜脈滴注免疫球蛋白
• 抗D免疫球蛋白
• TPO-RA

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲特發性血小板減少性紫癜市場當前和未來的需求。 此外，它還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 特發性血小板減少性紫癜治療市場的主要參與者是 Hoffman-L Roche、Amgen Inc、Grifols Biologicals Inc、GlaxoSmithKline Plc 等。 本節概述了競爭格局，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、聯合研究、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。 我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

• 本報告的內容
  • 目的
  • 目標受眾
  • 獨特的銷售主張 (USP) 及其提供的內容
• 調查範圍
• 調查方法
  • 市場調研過程
  • 市場研究方法

第 2 章執行摘要

• 市場亮點
• 全球市場概況

第3章特發性血小板減少性紫癜藥物產業分析

• 簡介 - 市場動態
• 市場驅動力
• 市場製約因素
• 市場機會
• 行業趨勢
• 波特的五力分析
• 市場吸引力分析
  • 市場吸引力分析：按產品
  • 市場吸引力分析：按地區

第四章價值鏈分析

• 價值鏈分析
• 原材料分析
  • 原材料清單
  • 原材料製造商列表
  • 主要原材料價格走勢
• 潛在買家名單
• 營銷渠道
  • 直接營銷
  • 間接營銷
  • 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章特發性血小板減少性紫癜藥物的全球市場分析：副產品

• 產品概覽
• 實際數據和預測數據
• 按產品分析
• 腎上腺皮質類固醇
• 靜脈注射免疫球蛋白療法
• 抗D免疫球蛋白
• TPO-RA

第7章特發性血小板減少性紫癜藥物的全球市場分析：按地區

• 區域展望
• 簡介
• 北美銷售分析
  • 概覽、歷史和預測銷售分析
  • 北美各部門的銷售分析
  • 北美銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 按細分市場進行的歐洲銷售分析
  • 按國家/地區劃分的歐洲銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 意大利銷售分析
  • 俄羅斯銷售分析
  • 其他歐洲銷售分析
• 亞太地區銷售分析
  • 概覽、歷史和未來銷售分析
  • 亞太地區各部門的銷售分析
  • 亞太國家/地區銷售分析
  • 在中國的銷售分析
  • 印度銷售分析
  • 日本的銷售分析
  • 韓國銷售分析
  • 澳大利亞銷售分析
  • 其他亞太地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 拉丁美洲各部門的銷售分析
  • 拉丁美洲國家/地區的銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利的銷售分析
  • 其他拉丁美洲銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 中東/非洲地區的銷售分析
  • 中東和非洲國家/地區的銷售分析
  • 沙特阿拉伯銷售分析
  • 阿聯酋銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 其他中東和非洲銷售分析

第8章：特發性血小板減少性紫癜藥物企業競爭格局

• 治療特發性血小板減少性紫癜藥物的市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第九章公司簡介

• 頂級公司的市場份額分析
• 市場集中度
• Hoffman-L Roche
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期發展狀況
• 安進公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Grifols Biologicals Inc.
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 葛蘭素史克公司。
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

The global demand for Idiopathic Thrombocytopenic Purpura Therapeutics Market is presumed to reach the market size of nearly USD 1347.54 MN by 2030 from USD 700.59 MN in 2022 with a CAGR of 8.52% under the study period 2023 - 2030.

Idiopathic thrombocytopenic purpura or ITP is an autoimmune disorder that leads to a low platelet count in the blood. Platelets are necessary for proper blood clotting, and its low count can cause excessive bleeding and bruising. ITP therapeutics refers to the drugs, treatments, and medical devices used to manage and treat idiopathic thrombocytopenic purpura 

Market Dynamics:

The prevalence of ITP is increasing globally due to factors such as ageing populations and a rise in autoimmune disorders. This is driving demand for ITP therapeutics market. Technological advancements in ITP therapeutics, such as the development of biological drugs, are improving treatment outcomes and driving the market growth. Governments around the world are providing financial support and incentives to promote the development and adoption of ITP therapeutics, driving the market growth. Increasing awareness about ITP and its treatment options is driving demand for ITP therapeutics as more individuals seek out effective treatment options. Despite the availability of some treatments, there is still a high unmet need for more effective and affordable ITP therapeutics, driving demand for new and improved treatments. The growing market for biologics, including monoclonal antibodies and other biologic drugs, is expected to drive the growth of the ITP therapeutics market as these drugs become increasingly popular for treating ITP. Insurance companies are providing coverage for ITP therapeutics, making them more accessible and affordable for individuals with ITP, which is driving demand for these treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of idiopathic thrombocytopenic purpura therapeutics. The growth and trends of idiopathic thrombocytopenic purpura therapeutics industry provide a holistic approach to this study. 

Market Segmentation:

This section of the idiopathic thrombocytopenic purpura therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Product

• Corticosteroids
• Intravenous Immunoglobulin
• Anti-D Immunoglobulin
• TPO-RA

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Idiopathic Thrombocytopenic Purpura Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the idiopathic thrombocytopenic purpura therapeutics market include Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc., and GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY PRODUCT

• 6.1 Overview by Product
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product
• 6.4 Corticosteroids Historic and Forecast Sales by Regions
• 6.5 Intravenous Immunoglobulin Historic and Forecast Sales by Regions
• 6.6 Anti-D Immunoglobulin Historic and Forecast Sales by Regions
• 6.7 TPO-RA Historic and Forecast Sales by Regions

7 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS COMPANIES

• 8.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Hoffman-L Roche
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Amgen Inc
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Grifols Biologicals Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. GlaxoSmithKline Plc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Corticosteroids Market Sales by Geography (USD MN)
• Intravenous Immunoglobulin Market Sales by Geography (USD MN)
• Anti-D Immunoglobulin Market Sales by Geography (USD MN)
• TPO-RA Market Sales by Geography (USD MN)
• Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Idiopathic Thrombocytopenic Purpura Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Corticosteroids Market Sales by Geography (USD MN)
• Intravenous Immunoglobulin Market Sales by Geography (USD MN)
• Anti-D Immunoglobulin Market Sales by Geography (USD MN)
• TPO-RA Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.